ILK and prostate cancer: In the present study, using two different androgen-independent human prostate cancer cell lines and DU-145 and PC-3, as in vitro experimental systems, we demonstrated that two distinct intracellular focal adhesion complex components, talin and ILK, are targeted by the lead quinazoline DZ-50 (Fig. 6).